Buy Rating Affirmed for Insmed on Positive Pipeline Prospects and Robust Revenue Forecasts
TipRanks · 15h ago
Guggenheim Maintains Buy on Insmed, Raises Price Target to $54
Benzinga · 1d ago
UBS Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $46
Benzinga · 1d ago
Weekly Report: what happened at INSM last week (0219-0223)?
Weekly Report · 2d ago
3 Best Stocks to Buy Now, 2/26/2024, According to Top Analysts 
TipRanks · 2d ago
Buy Rating Affirmed for Insmed on Strong Sales and Promising Trial Outlook
Analyst Joseph Schwartz of Leerink Partners maintained a Buy rating on Insmed (INSM) with a price target of $50.00. Insmed’s flagship product Arikayce posted revenues in line with expectations. The company is expected to have a double-digit growth trajectory in the coming years.
TipRanks · 2d ago
Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Insmed Incorporated (NASDAQ:INSM) reported its annual result last week. The company reported revenues of US$305m, in line with expectations, but also reported statutory losses of  US$5.34 per share. The shares are down 7.6% since the report, and are expected to fall further in the coming days. Insmed is forecast to report revenues of 18% growth in 2024, but analysts have increased their loss per share estimates for the business. There was no change to the consensus price target for Insmed's share price.
Simply Wall St · 3d ago
Buy Recommendation for Insmed: Underestimated Drug Potential and Solid Financials
TipRanks · 5d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 5d ago
Barclays Sticks to Its Buy Rating for Insmed (INSM)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and BioMarin Pharmaceutical (BMRN)
TipRanks · 5d ago
Insmed Strikes $500M Deal with Leerink for Growth and R&D
Insmed Incorporated has entered into a new agreement with Leerink Partners to potentially sell up to $500 million of its common stock. The flexible arrangement allows Insmed to support its commercial and development activities for its drug ARIKAYCE. The partnership is designed to bolster Insmed's financial positioning.
TipRanks · 6d ago
Insmed: Q4 Earnings Snapshot
Insmed Inc. Reports a loss of $186.1 million in its fourth quarter. Biopharmaceutical developing inhaled treatments for patients battling rare lung diseases posted revenue of $83.7 million. The Bridgewater, New Jersey-based company missed Wall Street expectations. For the year, the company reported a Loss of $749.6 million.
Barchart · 6d ago
Notable earnings before Thursday's open
Major earnings expected before the bell on Thursday include Dominion Energy (D) and Newmont (NEM) Other major earnings slated for release before Thursday's open include: Old Dominion Energy, Iron Mountain, Newmont and Nikola. The company will report its fourth quarter and full year earnings before the open.
Seeking Alpha · 02/21 14:42
Webull provides a variety of real-time INSM stock news. You can receive the latest news about Insmed Inc through multiple platforms. This information may help you make smarter investment decisions.
About INSM
Insmed Incorporated is a biopharmaceutical company. It is engaged in providing ARIKAYCE (amikacin liposome inhalation suspension) product, which is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developed for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).